Purple Biotech Ltd. (IL:PPBT)
TASE:PPBT
PPBT Stock Chart & Stats
1.20
>-0.01(-5.19%)
At close: 4:00 PM EST
1.20
>-0.01(-5.19%)
Day’s Range― - ―
52-Week Range1.00 - 5.70
Previous CloseN/A
Volume1.16M
Average Volume (3M)8.90M
Market Cap
₪18.58M
Enterprise Value-6.76M
Total Cash (Recent Filing)₪9.58M
Total Debt (Recent Filing)₪244.05K
Price to Earnings (P/E)―
Beta0.30
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.10
Shares Outstanding1,858,479,500
10 Day Avg. Volume1,387,469
30 Day Avg. Volume8,902,795
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet ResilienceVery low debt materially reduces near- to medium-term solvency risk and preserves financial optionality. For a clinical-stage biotech, low leverage supports flexibility to pursue partnerships, non-dilutive deals, or targeted financings without heavy interest burden, aiding program continuity.
CAPTN-3 Platform Scientific ProgressConcrete preclinical advances and a second named tri-specific antibody de-risk the CAPTN-3 platform structurally. Demonstrated in vivo efficacy, favorable therapeutic window and scalable manufacturability increase partner interest and the likelihood that one or more assets can progress into clinical studies and licensing discussions.
Near-term Cash Runway From 2025 FinancingA disclosed cash runway into 2027 gives management time to initiate IM1240 Phase 1 and advance program milestones without immediate refinancing. This runway reduces short-term execution disruption risk, enabling milestone-driven value creation and more orderly partner or financing negotiations.
Bears Say
Sustained Negative Cash FlowConsistent annual negative operating and free cash flow creates an enduring dependence on external financing. Even with improved burn trends, inability to self-fund R&D means recurring dilution or costly financing, which can erode shareholder value and constrain long-term strategic choices.
Widening Operating Losses And Minimal RevenueA pre-commercial income profile with negligible revenue and sharply widening losses in 2025 signals weak operating leverage. Without material commercialization or steady partner milestone income, continued losses increase probability of equity dilution and limit capacity to scale programs internally.
Leadership Transition RiskA planned CEO departure and active external search represent a durable governance and execution risk. Leadership changes can slow strategic decisions, fundraising, and trial starts; successor selection quality materially affects partner negotiations and the pace of clinical advancement over the next 6–18 months.
Purple Biotech News
PPBT FAQ
What was Purple Biotech Ltd.’s price range in the past 12 months?
Purple Biotech Ltd. lowest stock price was 1.00 and its highest was 5.70 in the past 12 months.
What is Purple Biotech Ltd.’s market cap?
Purple Biotech Ltd.’s market cap is ₪18.58M.
When is Purple Biotech Ltd.’s upcoming earnings report date?
Purple Biotech Ltd.’s upcoming earnings report date is May 27, 2026 which is in 61 days.
How were Purple Biotech Ltd.’s earnings last quarter?
Purple Biotech Ltd. released its earnings results on Feb 11, 2026. The company reported -4.1 earnings per share for the quarter, missing the consensus estimate of N/A by -4.1.
Is Purple Biotech Ltd. overvalued?
According to Wall Street analysts Purple Biotech Ltd.’s price is currently Overvalued.
Does Purple Biotech Ltd. pay dividends?
Purple Biotech Ltd. pays a Notavailable dividend of 249.549 which represents an annual dividend yield of N/A. See more information on Purple Biotech Ltd. dividends here
What is Purple Biotech Ltd.’s EPS estimate?
Purple Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Purple Biotech Ltd. have?
Purple Biotech Ltd. has 1,858,479,500 shares outstanding.
What happened to Purple Biotech Ltd.’s price movement after its last earnings report?
Purple Biotech Ltd. reported an EPS of -4.1 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Purple Biotech Ltd.?
Currently, no hedge funds are holding shares in IL:PPBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.